Navigation Links
ActiveSight and CHDI Leverage Fragment-Based Lead Discovery for Huntington Disease Therapies
Date:9/18/2007

. and High Q Foundation

CHDI, Inc. and the High Q Foundation, Inc. (High Q) are non-profit organizations that share the mission of bringing together academia, industry, governmental agencies, and other funding organizations in the search for Huntington Disease treatments.

CHDI, Inc. is pursuing a biotech approach to rapidly discover and develop drugs that prevent or slow Huntington Disease. Through collaborations with industrial and academic partners, CHDI, Inc. participates in all aspects of drug discovery and development from lead discovery to preclinical development. For more information about CHDI, Inc. and its collaborative programs please see http://www.chdi-inc.org.

High Q supports Huntington Disease research aimed at target identification and validation, the development and use of animal models, drug delivery, and the search for markers of disease progression. For more information about High Q and its support of Huntington Disease research please see http://www.highqfoundation.org.


'/>"/>
SOURCE ActiveSight
Copyright©2007 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3

Related medicine technology :

1. Major New Review Supports the Broader Potential of CeNeS COMT Inhibitor Discovery Programme
2. Discoverys KL-4 Surfactant Technology Demonstrates Novel Anti-Inflammatory Properties
3. Discovery Labs Presents Surfaxin and Aerosurf Data At the Pediatric Academic Societies Annual Meeting
4. Major Discovery Raises Prospect of Better Patient Care By Improving Platelet Life Span
5. Clinical Trial Results Suggest Long-Term Treatment Benefit of Tetrabenazine for Chorea Associated with Huntingtons Disease
6. Amarin Reports Top-Line Results of two Phase III Studies of Miraxion in Huntingtons Disease
7. Appendicitis: Evolving Tools to Diagnose a Classic Disease
8. Non-Invasive Diagnostic Tests for Celiac Disease
9. Corgenix Reports New Clinical Data Correlating AtherOx Technology With Vascular Disease
10. AVI BioPharma Partner Cook Medical Announces Completion of Patient Enrollment for APPRAISAL Phase II Clinical Trial for Treatment of Cardiovascular Disease
11. Samaritans Alzheimers Drug Caprospinol Suggests Brain May be Able to Heal From Alzheimers Disease
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/18/2008)...ed study will enroll newly diagnosed, elderly AML ...wswire/ -- Celator Pharmaceuticals today announced...omized Phase 2 clinical study of CPX-351 (Cytarabi...th newly diagnosed acute myeloid leukemia (AML). ,...eldman, MD at the Weill Medical College of Cornel...
(Date:11/13/2008)...Study Suggests Nutritional Supplements Prior to Su...re-USNewswire/ -- Identifying,malnutrition before ...dy,contouring will significantly decrease surgical...scar quality and boost patient energy levels,acco...and Reconstructive,Surgery(R), the official medica...
(Date:11/12/2008)...YORK, Nov. 12 A new stu... of Cell will help answer the,question, what cause...questions in the medical research into,Parkinson,s... brain to die,in the first place. Answering this q...e are two nearly identical types of brain cells th...
(Date:11/12/2008)...ELAND, Ohio and LOD, Israel, November 12 /PRNewswi...ical Center, NY indicated that,patient-specific CT...or,(ANGIO Mentor(TM), Simbionix US) with high face... simulation improved the operative flow,increased...decreased,overall operative and fluoroscopy time a...
Breaking Medicine Technology:Celator(R) Pharmaceuticals Announces Enrollment of First Patient in Phase 2 Study with CPX-351 2Celator(R) Pharmaceuticals Announces Enrollment of First Patient in Phase 2 Study with CPX-351 3Plastic Surgeons Warn of Malnutrition in Body Contouring Patients 2A Window Into Parkinson's Disease 2Vascular Surgeons Agree: Case Rehearsal Improves Outcomes 2Rosetta Genomics Announces Expansion of its MicroRNA Intellectual Property Estate 4902 1Rosetta Genomics Announces Expansion of its MicroRNA Intellectual Property Estate 4902 2Rosetta Genomics Announces Expansion of its MicroRNA Intellectual Property Estate 4902 3Rosetta Genomics Announces Expansion of its MicroRNA Intellectual Property Estate 4902 4Cynosure Introduces Smartlipo MPX 28TM 29 Dual Wavelength Workstation for LaserBodySculpting 28SM 29 4900 1Cynosure Introduces Smartlipo MPX 28TM 29 Dual Wavelength Workstation for LaserBodySculpting 28SM 29 4900 2Cynosure Introduces Smartlipo MPX 28TM 29 Dual Wavelength Workstation for LaserBodySculpting 28SM 29 4900 3Cynosure Introduces Smartlipo MPX 28TM 29 Dual Wavelength Workstation for LaserBodySculpting 28SM 29 4900 4Cynosure Introduces Smartlipo MPX 28TM 29 Dual Wavelength Workstation for LaserBodySculpting 28SM 29 4900 5Alfacell Announces Retirement of Chief Executive Officer 4898 1Alfacell Announces Retirement of Chief Executive Officer 4898 2Alfacell Announces Retirement of Chief Executive Officer 4898 3Alfacell Announces Retirement of Chief Executive Officer 4898 4Neuralstem Announces Issuance of Core Technology Patent in Europe 1912 1Neuralstem Announces Issuance of Core Technology Patent in Europe 1912 2
...ans 350,000 Locations Across the Genome From 242,P...te to Acute,Lymphoblastic Leukemia, Suggesting New...ch 07, 2007 /PRNewswire/ -- Investigators at,St. J...reviously,unsuspected mutations that contribute to...ukemia (ALL), the most common cancer in,children. ...
... PARK, N.C., Mar 8, 2007 (CCNMatthews via COMTEX,N...)(AMEX:ADH), a,biopharmaceutical company with a br...nt, today announced that Dr. Antonella,Perotti, MD...dation, an investigator in Adherex,s European Phas...data today from that study at,the 5th Internationa...
Other Medicine Technology:Major Gene Study Uncovers Secrets of Leukemia 2Major Gene Study Uncovers Secrets of Leukemia 3Data From Adherex's European Phase Ib/II Trial of ADH-1 to be,Presented at International Symposium on Targeted Anticancer,Therapies 2Data From Adherex's European Phase Ib/II Trial of ADH-1 to be,Presented at International Symposium on Targeted Anticancer,Therapies 3
(Date:11/21/2008)... 11.4% Shareholders Intend To Vigorously Protect ... CINCINNATI, Nov. 21 D...ay filed an amendment to their Schedule 13D with t...roup previously filed a 13D disclosing ownership o...ch operates 77 LasikPlus fixed-site laser vision c...
(Date:11/21/2008)... NEW YORK, Nov. 21 The general me...voted to induct three new individuals at their Ann... the Pierre hotel in New York. A,Lifetime Achieve...nductees into the Medical Advertising Hall of Fame...ing career with an account position,at Sudler &am...
(Date:11/21/2008)... MONTVALE, N.J., Nov. 21 /PRNewswire-FirstCall/ -...announced that its shareholders overwhelmingly app...the acquisition of Barr by Teva Pharmaceuticals In...y,s vote demonstrated the overwhelming support of ...uce L. Downey, Barr,s Chairman and CEO. "We are pl...
(Date:11/21/2008)... Experiments in mice find running increases produ...ov. 21 (HealthDay News) -- In experiments in mice,...oduction of brain stem cells usually seen with agi...able restoration of the brain,s ability to stave o...o restore a neurochemical that is essential for th...
Breaking Medicine News(10 mins):Health News:Founders & Former Executive Management Team of LCA-Vision Seek Change to Rescue Company 2Health News:Founders & Former Executive Management Team of LCA-Vision Seek Change to Rescue Company 3Health News:Founders & Former Executive Management Team of LCA-Vision Seek Change to Rescue Company 4Health News:Founders & Former Executive Management Team of LCA-Vision Seek Change to Rescue Company 5Health News:Founders & Former Executive Management Team of LCA-Vision Seek Change to Rescue Company 6Health News:Founders & Former Executive Management Team of LCA-Vision Seek Change to Rescue Company 7Health News:Ronald Pantello, Harry Sweeney, and David Wood Voted Into Medical Advertising Hall of Fame. 2Health News:Ronald Pantello, Harry Sweeney, and David Wood Voted Into Medical Advertising Hall of Fame. 3Health News:Barr Shareholders Approve Pending Teva Acquisition 2Health News:Barr Shareholders Approve Pending Teva Acquisition 3Health News:Barr Shareholders Approve Pending Teva Acquisition 4Health News:Exercise Keeps the Brain Young 2
...rs of the Holocaust are more likely to suffer from...ne Raviv and his colleagues at Israel's //Haifa Un...ed by the near-starvation of European Jews during ...ers looked at the incidence and death rate from ca...
...tors in Toronto are desperately trying to reattach... his foot in a freak accident that involved his fa...g to York Region police the boys father had been r...p unexpectedly behind him. Constable Laurie Perks ...
... University researchers plan to ask women to donat...ryonic stem cells matched to patients // which the... debilitating diseases such as diabates or neurode...ract embryonic stem (ES) cells after creating huma...
...research has revealed that taking antibiotics for ...to 10 days is equally effective in the treatment o...this could also help to curb the rising problem of...ria, Lead researcher Dr. Jan M Prins, an internis...
Other Medicine News:Health News:Pneumonia Effectively Treated with Short-Term Antibiotic Course 2
... is a national reference laboratory and a worldwid...elopment. ARUP offers an extensive test menu of hi...and anatomic pathology. Owned by the University of...n half of the nation's university teaching hospita...
... is a national reference laboratory and a worldwid...elopment. ARUP offers an extensive test menu of hi...and anatomic pathology. Owned by the University of...n half of the nation's university teaching hospita...
... is a national reference laboratory and a worldwid...elopment. ARUP offers an extensive test menu of hi...and anatomic pathology. Owned by the University of...n half of the nation's university teaching hospita...
... is a national reference laboratory and a worldwid...elopment. ARUP offers an extensive test menu of hi...and anatomic pathology. Owned by the University of...n half of the nation's university teaching hospita...
Medicine Products: